Can-Fite BioPharma Ltd.
10 Bareket Street
Kiryat Matalon Petah Tikva, 4951778, Israel
Phone: 972 3 924 1114
http://www.canfite.com

Company Overview

Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion dollar markets in the treatment of autoimmune inflammatory and liver diseases. Can-Fite's drugs have an excellent safety profile with experience in over 1,000 patients. The Company's lead drug candidate, Piclidenoson (CF101), is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver drug Namodenoson (CF102) completed patient enrollment in a Phase II trial for patients with advanced liver cancer and is in a Phase II trial for the treatment of NAFLD/NASH. Can-Fite's intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with ~$16 million received to date.

EQUITY OVERVIEW

NYSE American: CANF; TASE: CFBI

1 ADR = 2 ordinary TASE shares
Market Cap (11/06/18): ~$27 M
52 Week Range (11/06/18): $1.12 - $2.75
3 Month Average Daily Volume: 63,918
Ordinary Shares Outstanding: 40M
Cash Balance (6/30/18): $5.8M; $2M received from CMS in August

ANALYST COVERAGE

H.C. Wainwright; Zacks

CORPORATE PARTNERSHIPS

Out-licensed in select territories with ~$16 M upfront and milestone payments received.

Drug	Partner	Territory
Piclidenoson	**Cipher Pharma.**	Canada
	Gebro Pharma	Spain Switzerland Austria
	Kwang Dong	South Korea
	CMS	China
Namodenoson	**Chong Kun Dang**	South Korea
	CMS	China

UPCOMING MILESTONES & MARKETS

Milestone	When	Mkt*
Piclidenoson: Rheumatoid Arthritis **Phase III Trial**	Ongoing	$34.6B in 2017
Piclidenoson: Psoriasis **Phase III Trial**	Ongoing	$11.4B in 2020
Namodenoson: Liver Cancer **Announce Phase II Results**	Q1 2019	$1.4B in 2019
Namodenoson: NAFLD/NASH **Announce Phase II Results**	Q2 2019	$35B In 2025
CF602 Sexual Dysfunction **Preclinical Studies Ongoing**	Ongoing	$3.2B In 2022

**Sources: Visiongain, GlobalData, Datamonitor, Grand View, Deutsche Bank*

Investor Contact:

Motti Farbstein, CFO, + 972 3 924 1114

Disclaimer: Except for historical information contained herein, the statements in this fact sheet are "forward looking" within the meaning of the Private Securities Litigation Act of 1995. This fact sheet includes estimates and projections and, as such, reflects only management's current expectations. A fuller discussion of Can-Fite BioPharma Ltd's risks and uncertainties are described in the Company's filings with the Securities and Exchange Commission, which should be reviewed in conjunction with this overview.

Drug Development Pipeline



Investment Highlights

Platform: Specific Target on Diseased Cells

Can-Fite's platform technology is based on the finding that the Gi protein-coupled A3 adenosine receptor (A3AR) is over-expressed in inflammatory and cancer cells. The Company's proprietary compounds target and bind with A3AR and induce specific cell death of cancer and inflammatory cells. This creates a targeted anti-cancer and anti-inflammatory effect, while leaving normal cells unharmed. A3AR is also a predictive biomarker which helps to identify individual patients' responsiveness to the Company's drugs. The biomarker is used in the Phase III psoriasis study.

Phase III Arthritis Drug Being Evaluated as Alternative to Standard of Care

Can-Fite is currently enrolling patients in its pivotal Phase III ACRobat trial of Piclidenoson in the treatment of rheumatoid arthritis which is slated to enroll approximately 500 patients. Piclidenoson is being evaluated as a first line therapy and an alternative to Methotrexate, the current standard of care and most widely used rheumatoid arthritis drug.

Phase III Psoriasis Study Ongoing

Can-Fite is currently enrolling patients in its pivotal Phase III trial for Piclidenoson in the treatment of psoriasis. The study is expected to enroll approximately 400 patients with moderate-to-severe psoriasis. The trial's primary endpoint will test efficacy as compared to a placebo, while the secondary endpoint will test Piclidenoson against Otezla®, a widely used psoriasis drug from Celgene.

Phase II Liver Cancer Study with Fast Track & Orphan Drug Designations

Can-Fite completed enrollment in its Phase II study of Namodenoson in HCC, the most common form of liver cancer, and expects to announce results in Q1 2019. The U.S. FDA granted Can-Fite Fast Track Designation for Namodenoson as a second line treatment for HCC in patients who have previously received Nexavar (sorafenib). Namodenoson has Orphan Drug Designation in both the U.S. and EU for the treatment of HCC.

Phase II Trial in NAFLD/NASH for $35B Market in 2025

Can-Fite is currently enrolling patients in a Phase II trial of Namodenoson in the treatment of non-alcoholic fatty liver disease (NAFLD), the precursor to non-alcoholic steatohepatitis (NASH). Can-Fite expects to announce top-line results in H1 2019. There is currently no U.S. FDA approved drug for NAFLD/NASH, an unmet medical need projected to become a $35-$40 billion market by 2025.